华神科技(000790) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥199,302,734.03, a decrease of 7.25% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥8,566,574.03, down 15.03% year-on-year[4] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥14,593,514.91, an increase of 40.49% compared to the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.0137, a decrease of 16.46% year-on-year[4] - The net profit for Q3 2022 was CNY 22,599,592.44, a decrease of 27.5% compared to CNY 31,156,008.87 in Q3 2021[26] - Operating profit for Q3 2022 was CNY 27,193,306.63, down 30.6% from CNY 39,151,620.99 in the same period last year[26] - Total revenue from operating activities was CNY 600,483,424.39, an increase of 10.4% compared to CNY 543,949,664.38 in Q3 2021[29] - Basic and diluted earnings per share for Q3 2022 were CNY 0.0415, down from CNY 0.0566 in Q3 2021[26] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥1,485,607,366.30, reflecting a 9.95% increase from the end of the previous year[4] - The company's inventory increased by 53.39% to ¥134,595,409.09, primarily due to the acquisition of a subsidiary[10] - The long-term equity investments increased by 100% to ¥56,595,111.01, attributed to new investments in the Shandong Lingkai project[10] - The goodwill on the balance sheet reached ¥57,599,644.30, resulting from the premium paid in the acquisition of a subsidiary[10] - Total assets as of September 30, 2022, were CNY 1,485,607,366.30, compared to CNY 1,351,112,420.20 at the beginning of the year, reflecting an increase of 9.9%[23] - Total liabilities increased to CNY 508,824,114.93 from CNY 369,676,411.67, representing a rise of 37.6%[23] - Long-term borrowings reached ¥99,886,000.00, marking a 100% increase as a result of new bank financing[11] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥53,666,005.29, a significant improvement of 175.40% compared to the same period last year[4] - Cash received from operating activities decreased by 44.66% to ¥20,589,513.90, mainly due to reduced performance guarantees and other deposits[15] - Cash paid for the acquisition of fixed assets increased by 34.97% to ¥142,934,183.27, reflecting higher asset purchases[15] - The company secured bank loans totaling ¥200,000,000.00, a 1233.33% increase compared to ¥15,000,000.00 in the previous period[15] - Financing activities generated a net cash inflow of CNY 112,587,254.38, compared to CNY 20,762,167.16 in the same period last year[30] Expenses - R&D expenses increased by 31.68% to ¥17,824,086.28 due to higher investment in research and development[13] - Financial expenses rose by 190.08% to ¥1,823,182.55 primarily due to increased interest expenses from bank loans[13] - Selling expenses for Q3 2022 were CNY 137,717,051.81, a decrease of 14.2% from CNY 160,543,277.28 in Q3 2021[26] - The company incurred a financial expense of CNY 1,823,182.55, compared to a financial income of CNY 2,024,049.06 in the previous year[26] Shareholder Equity - The company's minority shareholders' equity rose by 51.36% to ¥7,479,165.46, driven by capital contributions from minority shareholders[11] - The company's equity attributable to shareholders decreased to CNY 969,304,085.91 from CNY 976,494,790.70, a decline of 0.9%[23] Strategic Initiatives - The company plans to invest up to ¥200,000,000.00 in Shanghai Lingkai Pharmaceutical Technology Co., acquiring a 5.7143% stake to enhance collaboration in the CDMO industry[18] - The company adjusted its 2021 restricted stock incentive plan to align with the current operating environment, ensuring better motivation and stability for the team[19]